Innovation
Innovation drives disease prevention
We're uniting science, technology and talent to get ahead of RSV
RSV
0:31
Press releases
- US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
- GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
- Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone


Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features